


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1 (Currently amended). A pharmaceutical composition for dry powder inhalation ~~inhaled use~~ in the respiratory tract of a mammal, comprising a compound according to Formula (I) hereinbelow:



wherein

R2 and R3 are, independently, selected from the group consisting of straight or branched chain lower alkyl (having from 1 to 6 carbon atoms), cycloalkyl (having from 5 to 6 carbon atoms), 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms, and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X⁻ represents an anion associated with the positive charge of the N atom; and a pharmaceutically acceptable carrier or diluent suitable for dry powder oral [[or nasal]] inhalation.

2 (previously presented). A pharmaceutical composition according to claim 1 wherein the orientation of the alkyl chain attached to the tropane ring is endo.

3 (previously presented). A pharmaceutical composition according to claim 2 wherein the compound of Formula (I) is selected from the group consisting of: (3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; and

(3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane 4-methylbenzenesulfonate.

4 (previously presented). A pharmaceutical composition according to claim 1 wherein X⁻ is selected from the group consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.

5. (Cancelled)

6. (currently amended) A method of inhibiting the binding of acetylcholine to a acetylcholine receptor in a mammal in need thereof, which comprises contacting the acetylcholine receptor with an effective amount of a composition according to claim 1, and wherein the method of contacting the receptor with the composition is via inhalation by the mouth [[or nose]] of the mammal.

7. (currently amended) A method of [[a]] inhibiting the binding of acetylcholine to a M₃ muscarinic acetylcholine receptor in the respiratory tract of a mammal in need thereof, which comprises contacting the M₃ muscarinic acetylcholine receptor with an effective amount of a composition according to claim 1 and wherein the method of contacting the receptor with the composition is via inhalation by the mouth [[or nose]] of the mammal.

8. (previously presented) A method according to claim 7 wherein the binding of the M₃ muscarinic acetylcholine receptor is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis.

9. (currently amended) A method according to claim 7 wherein administration is via inhalation via the mouth from a medicament dispenser which is a reservoir dry powder inhaler.

10. (currently amended) A method according to claim 7 wherein administration is via inhalation via the mouth from a medicament dispenser which is ~~selected from a~~

~~reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.~~

11. (previously presented) A method according to claim 7 wherein the composition has a duration of action of 12 hours or more and the mammal is a human.

12. (previously presented) A method according to claim 11 wherein the composition has a duration of action of 24 hours or more.

13. (previously presented) A method according to claim 12 wherein the composition has a duration of action of 36 hours or more.

14. (previously presented) A method according to claim 7 wherein administration is via inhalation via the nose.

15. (currently amended) A method of treating chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis in a human in need thereof, comprising administering to said human by inhalation via the mouth [[or nose]], an effective amount of a composition according to Claim 1.

16. (new) The method according to Claim 15 wherein the treatment is of chronic obstructive lung disease or asthma.